Table 1.
Demographics, Inflammatory markers, treatment and outcomes measured in 14 patients.
| Proportion- Mean(±SD), Median(range) | |
|---|---|
| Demographics | |
| Age (years) | Mean-49.14 (±12.50), Median-51.5 (28−65) |
| Gender | Male-11(78.6%), Female-3(21.4%) |
| BMI (kg/m2) | Mean-29.66 (±4.99), Median 32.5 (24−41) |
| Comorbidities | 10(57.1%) |
| Interval between symptoms onset to sequential therapy (days) | Mean = 16.93 (±9.40), Median 9 (6−21) |
| Treatment | |
| Anti-viral agent | HCQ -35.7%, Favipiravir- 42.9%, Lopinavir/ritonavir-71% |
| Outcomes | |
| Day 7 Mortality Day 28 mortality |
3 (21.4%) 4 (28.6%) |
| Complications (Hypotension) | 3 (21.4%) |
| Interval between sequential therapy and negative RT-PCR for SARS-CoV-2 (days) | Mean-10.33 (±5.20), Median 8 (3−18) |
| Interval between sequential therapy and removal of IMV (days) | Mean -18.63 (±17.85), Median 6 (2−46) |
| ICU-Length of stay (days) | Mean = 26.43 (±17.77), Median 12 (5−42) |
| IMV-Length of stay (days) | Mean = 28.86 (±18.45), Median 6.5 (5−36) |
| Hospital- Length of stay (days) | Mean = 35.64 (±16.98), Median 18 (12−47) |
| Variables | Before therapy, Mean ± SD | 7 days after therapy Mean ± SD | p value |
|---|---|---|---|
| Body temperature (ºC) | 37.24 ± 0.92 | 37.16 ± 0.77 | 0.81 |
| PaO2/Fio2 ratio (mm of Hg) | 138.89 ± 41.90 | 224.78 ± 136.35 | 0.08 |
| Ferritin (ng/mL) | 1416.25 ± 1150.62 | 1051.42 ± 740.96 | 0.22 |
| D-dimer (μg/mL) | 4.20 ± 5.46 | 4.21 ± 5.93 | 0.51 |
| LDH (U/L) | 462.73 ± 178.66 | 402.45 ± 149.05 | 0.23 |
| CRP (μg/mL) | 86.74 ± 79.86 | 30.56 ± 30.73 | 0.03 |
| Lymphocyte count (x109/L) | 0.70 ± 0.54 | 1.04 ± 0.49 | 0.27 |
p value less than 0.05 is significant.
BMI- body mass index, CRP- C-reactive protein, HCQ-hydroxychloroquine, ICU-intensive care unit, IMV-Invasive mechanical ventilation, LDH- lactate dehydrogenase, RT-PCR-reverse transcriptase polymerase chain reaction, SARS-CoV-2-severe acute respiratory syndrome coronavirus 2, SD-standard deviation.